等待開盤 02-05 09:30:00 美东时间
-1.070
-3.90%
今日重点评级关注:Benchmark:维持Charter Communications"买入"评级,目标价从425美元升至455美元;BTIG:维持LifeStance Health Gr"买入"评级,目标价从10美元升至11美元
02-03 09:06
Wells Fargo analyst Benjamin Burnett initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Overweight rating and announces Price Target of $43.
02-02 22:47
CLINICAL AND PIPELINE UPDATESRapport is prioritizing programs it believes have the greatest potential to deliver meaningful impact for patients and long-term value for the Company. This disciplined approach positions the
01-07 20:12
今日重点评级关注:Chardan Capital:维持Senti Biosciences"买入"评级,目标价从12美元升至13美元;Guggenheim:维持Praxis Precision Medicine"买入"评级,目标价从540美元升至760美元
2025-12-10 10:33
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients' disease
2025-12-05 22:03
今日重点评级关注:富国银行:维持Annexon"超配"评级,目标价从14美元升至27美元;瑞穗:上调Relmada Therapeutics评级至"跑赢大市",目标价从1美元升至10美元
2025-11-20 10:28
BTIG analyst Kambiz Yazdi initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $47.
2025-11-19 18:12
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
2025-11-10 17:17
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
2025-11-10 10:22
Citizens analyst Jason N. Butler maintains Rapport Therapeutics (NASDAQ:RAPP) with a Market Outperform and raises the price target from $77 to $80.
2025-11-07 22:21